also described that HLA-A but not HLA-B/C downmodulation correlates with longer DFS in patients with low-stage CRC, suggesting an anti-tumour role of NK cells or attenuated aggressiveness of MSI tumours (37). The gene discussed is HLA-B; the disease is neoplasm.